📊 XTNT Key Takeaways
Is Xtant Medical Holdings, Inc. (XTNT) a Good Investment?
Xtant Medical demonstrates strong fundamental momentum with 14.2% revenue growth and exceptional 130% net income acceleration, indicating emerging operating leverage in a medical device business. A fortress balance sheet with 0.22x D/E leverage, strong liquidity (2.65x current ratio), and consistent free cash flow generation ($10.2M) provide substantial downside protection.
Why Buy Xtant Medical Holdings, Inc. Stock? XTNT Key Strengths
- Strong revenue growth of 14.2% YoY with exceptional net income growth of 130%+, demonstrating operating leverage is improving
- Fortress balance sheet: low leverage (0.22x D/E), strong liquidity (2.65x current ratio), $17.1M cash reserves (18% of assets)
- Excellent 62.9% gross margin typical of medical device industry, supporting substantial profitability upside potential
- Positive free cash flow generation of $10.2M (7.6% FCF margin) with disciplined CapEx spending of only $2.4M
XTNT Stock Risks: Xtant Medical Holdings, Inc. Investment Risks
- Operating margin constrained at only 5.4% and net margin at 3.7%, limiting profitability expansion and leaving little room for error
- Interest coverage ratio of 2.0x is concerning; any material revenue decline could create debt service stress
- Minimal insider buying activity (1 Form 4 filing in 90 days) provides limited visibility into management confidence
- Modest returns on equity (9.8%) and assets (5.3%) indicate suboptimal capital efficiency despite capital-light model
Key Metrics to Watch
- Operating margin expansion trajectory - critical to validate that operating leverage thesis is sustainable
- Interest coverage ratio trend - must improve above 3.0x to significantly reduce financial risk profile
- Free cash flow conversion and sustainability relative to net income growth acceleration
- Gross margin stability - any compression would signal product mix pressure or competitive pricing challenges
Xtant Medical Holdings, Inc. (XTNT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.65x current ratio provides a solid financial cushion.
XTNT Profit Margin, ROE & Profitability Analysis
XTNT vs Healthcare Sector: How Xtant Medical Holdings, Inc. Compares
How Xtant Medical Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xtant Medical Holdings, Inc. Stock Overvalued? XTNT Valuation Analysis 2026
Based on fundamental analysis, Xtant Medical Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xtant Medical Holdings, Inc. Balance Sheet: XTNT Debt, Cash & Liquidity
XTNT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xtant Medical Holdings, Inc.'s revenue has grown significantly by 142% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.12 indicates the company is currently unprofitable.
XTNT Revenue Growth, EPS Growth & YoY Performance
XTNT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $27.9M | $58.0K | $0.01 |
| Q2 2025 | $29.9M | $58.0K | $0.02 |
| Q1 2025 | $27.9M | $58.0K | $0.00 |
| Q3 2024 | $25.0M | -$2.1M | $0.04 |
| Q2 2024 | $20.2M | -$2.1M | $-0.02 |
| Q1 2024 | $17.9M | -$2.1M | $-0.02 |
| Q3 2023 | $14.5M | -$1.7M | $-0.03 |
| Q2 2023 | $15.3M | -$1.7M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xtant Medical Holdings, Inc. Dividends, Buybacks & Capital Allocation
XTNT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xtant Medical Holdings, Inc. (CIK: 0001453593)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XTNT
What is the AI rating for XTNT?
Xtant Medical Holdings, Inc. (XTNT) has an AI rating of BUY with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XTNT's key strengths?
Claude: Strong revenue growth of 14.2% YoY with exceptional net income growth of 130%+, demonstrating operating leverage is improving. Fortress balance sheet: low leverage (0.22x D/E), strong liquidity (2.65x current ratio), $17.1M cash reserves (18% of assets).
What are the risks of investing in XTNT?
Claude: Operating margin constrained at only 5.4% and net margin at 3.7%, limiting profitability expansion and leaving little room for error. Interest coverage ratio of 2.0x is concerning; any material revenue decline could create debt service stress.
What is XTNT's revenue and growth?
Xtant Medical Holdings, Inc. reported revenue of $133.9M.
Does XTNT pay dividends?
Xtant Medical Holdings, Inc. does not currently pay dividends.
Where can I find XTNT SEC filings?
Official SEC filings for Xtant Medical Holdings, Inc. (CIK: 0001453593) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XTNT's EPS?
Xtant Medical Holdings, Inc. has a diluted EPS of $0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XTNT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Xtant Medical Holdings, Inc. has a BUY rating with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is XTNT stock overvalued or undervalued?
Valuation metrics for XTNT: ROE of 9.8% (sector avg: 15%), net margin of 3.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XTNT stock in 2026?
Our dual AI analysis gives Xtant Medical Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XTNT's free cash flow?
Xtant Medical Holdings, Inc.'s operating cash flow is $12.5M, with capital expenditures of $2.4M. FCF margin is 7.6%.
How does XTNT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 3.7% (avg: 12%), ROE 9.8% (avg: 15%), current ratio 2.65 (avg: 2).